

Herpes Zoster Non-Live Recombinant Vaccine (Shingrix®)

Revision Date: January 29, 2024

Rationale for Update:

- Expanded indications for provincially funded vaccine to include autologous HSCT recipients 18 years of age and older.

Please consult the Product Monograph¹ for further information about the vaccine.	
	SHINGRIX®
Manufacturer	GlaxoSmithKline Inc.
Licensed use	Individuals 50 years of age and older. Individuals 18 years of age and older who are or will be at increased risk of HZ due to immunodeficiency or immunosuppression caused by known disease or therapy
Indications for use of provincially funded vaccine	<ul style="list-style-type: none">Solid Organ Transplant recipients 18 years of age and older (pre and post solid organ transplant).² See Immunization of Adult Solid Organ Transplant Candidates and Recipients for additional information.Autologous Hematopoietic Stem Cell Transplant (HSCT) recipients 18 years of age and older (post HSCT).³ See Immunization for Adult Hematopoietic Stem Cell Transplant Recipients for additional information.
Dose	0.5 mL (entire contents of the reconstituted vial)
Route	Intramuscular injection
Schedule	Primary Series: <ul style="list-style-type: none">❖ Dose 1: Day 0¹❖ Dose 2: Two to six months later¹ Notes: <ul style="list-style-type: none">Persons with active HZ should not be immunized with HZ vaccine.⁴ Vaccine may be considered at least one year after an episode of HZ disease.⁴If individuals have received Zostavax®, an interval of one year is recommended between live attenuated Herpes Zoster (Zostavax®) and Shingrix®.^{4,5}
Administration with other vaccines	<ul style="list-style-type: none">Shingrix® may be administered concomitantly with, or at any time before or after, other inactivated vaccines or live vaccines protecting against a different disease.^{4,5}The vaccines should be administered at different injection sites.^{1,4}

Herpes Zoster Non-Live Recombinant Vaccine (Shingrix®)

Preparation	<ul style="list-style-type: none"> • Shingrix® must be reconstituted prior to administration.¹ • Withdraw the entire contents of the vial containing the adjuvant suspension into a sterile syringe. • Add the entire contents of the syringe into the vial containing the lyophilized powder. • Shake gently until the lyophilized powder is completely dissolved. • The reconstituted vaccine is an opalescent, colourless to pale brownish liquid.
Storage and Handling	<ul style="list-style-type: none"> • Store both lyophilized vial and adjuvant solution at +2°C to +8°C.¹ • Protect from light.
Contraindications	<ul style="list-style-type: none"> • Known severe hypersensitivity to any component of the vaccine.¹ • Anaphylaxis to a previous dose of the vaccine.^{1,4}
Precautions	<ul style="list-style-type: none"> • Shingrix® is not indicated for prevention of primary varicella infection or for the treatment of herpes zoster (HZ) or postherpetic neuralgia (PHN).¹ • There are limited data available on the use of Shingrix® in immunocompromised adults 50 years of age or older.¹ • Fever and shivering were more frequently reported when Pneumococcal Vaccine, 23-valent Polysaccharide (PPV23) vaccine was co-administered with Shingrix.¹
Possible reactions	See Product Monograph
Pregnancy	There are no data on the use of Shingrix® in pregnant women, therefore use with caution. ^{1,4,5}
Lactation	There are no data on the use of Shingrix® in breastfeeding women, therefore use with caution. ^{1,4,5}
Program Notes	<ul style="list-style-type: none"> • October 13, 2017 - licensed for use in Canada. • September 1, 2021 – implemented for solid organ transplant recipients 18 years of age and older. • January 28, 2022 – updated to include Health Canada approval for the prevention of herpes zoster (HZ) in individuals 18 years of age and older who are or will be at increased risk of HZ due to immunodeficiency or immunosuppression caused by known disease or therapy. • March 1, 2023- updated to include reports of fever and shivering when co-administered with Pneumococcal 23-valent Polysaccharide (PPV23) Vaccine. • January 29, 2024 - Expanded indications for provincially funded vaccine to include autologous HSCT recipients 18 years of age and older.

Herpes Zoster Non-Live Recombinant Vaccine (Shingrix®)

References

- ¹ GlaxoSmithKline (2022, November 15). Shingrix®: Herpes Zoster vaccine (non-live recombinant, AS01_B adjuvanted). *Product Monograph*. <https://ca.gsk.com/media/6259/shingrix-pm-en.pdf>
- ² Expert opinion of Alberta Infectious Disease and Solid Organ Transplant physicians. (November 2019).
- ³ Expert opinion of Alberta HSCT physicians. (November 2023).
- ⁴ National Advisory Committee on Immunization. (2018). Canadian Immunization Guide (Evergreen ed.). Ottawa, On: Public Health Agency of Canada. [https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-8-herpes-zoster-\(shingles\)-vaccine.html#a9](https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-8-herpes-zoster-(shingles)-vaccine.html#a9).
- ⁵ National Advisory Committee on Immunization. (2018). Updated Recommendations on the Use of Herpes Zoster Vaccines. <https://www.canada.ca/en/services/health/publications/healthy-living/updated-recommendations-use-herpes-zoster-vaccines.html#a6>